Amanda J Clark1, Kathy Jabs2, Tracy E Hunley2, Deborah P Jones2, Rene G VanDeVoorde2, Carl Anderson2, Liping Du3, Jianyong Zhong2,4, Agnes B Fogo2,4,5, Haichun Yang2,4, Valentina Kon6. 1. Department of Pediatrics, Monroe Carrell Children's Hospital at Vanderbilt, Nashville, TN, USA. 2. Division of Pediatric Nephrology, Monroe Carrell Children's Hospital at Vanderbilt, Nashville, TN, USA. 3. Department of Biostatistics, Vanderbilt Center for Quantitative Sciences, Nashville, TN, USA. 4. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Division of Pediatric Nephrology, Monroe Carrell Children's Hospital at Vanderbilt, Nashville, TN, USA. Valentina.Kon@vumc.org.
Abstract
BACKGROUND: Although high-density lipoprotein (HDL) modulates many cell types in the cardiovascular system, little is known about HDL in the kidney. We assessed urinary excretion of apolipoprotein AI (apoAI), the main protein in HDL. METHODS: We enrolled 228 children with various kidney disorders and 40 controls. Urinary apoAI, albumin, and other markers of kidney damage were measured using ELISA, apoAI isoforms with Western blot, and renal biopsies stained for apoAI. RESULTS: Patients followed in nephrology clinic had elevated urinary apoAI vs. controls (median 0.074 μg/mg; interquartile range (IQR) 0.0160-0.560, vs. 0.019 μg/mg; IQR 0.004-0.118, p < 0.001). Patients with tubulopathies, renal dysplasia/congenital anomalies of the kidney and urogenital tract, glomerulonephritis, and nephrotic syndrome (NS) in relapse had the greatest elevations (p ≤ 0.01). Patients with NS in remission, nephrolithiasis, polycystic kidney disease, transplant, or hypertension were not different from controls. Although all NS in relapse had higher apoAI excretion than in remission (0.159 vs. 0.0355 μg/mg, p = 0.01), this was largely driven by patients with focal segmental glomerulosclerosis (FSGS). Many patients, especially with FSGS, had increased urinary apoAI isoforms. Biopsies from FSGS patients showed increased apoAI staining at proximal tubule brush border, compared to diffuse cytoplasmic distribution in minimal change disease. CONCLUSIONS: Children with kidney disease have variably increased urinary apoAI depending on underlying disease. Urine apoAI is particularly elevated in diseases affecting proximal tubules. Kidney disease is also associated with high molecular weight (HMW) apoAI isoforms in urine, especially FSGS. Whether abnormal urinary apoAI is a marker or contributor to renal disease awaits further study.
BACKGROUND: Although high-density lipoprotein (HDL) modulates many cell types in the cardiovascular system, little is known about HDL in the kidney. We assessed urinary excretion of apolipoprotein AI (apoAI), the main protein in HDL. METHODS: We enrolled 228 children with various kidney disorders and 40 controls. Urinary apoAI, albumin, and other markers of kidney damage were measured using ELISA, apoAI isoforms with Western blot, and renal biopsies stained for apoAI. RESULTS:Patients followed in nephrology clinic had elevated urinary apoAI vs. controls (median 0.074 μg/mg; interquartile range (IQR) 0.0160-0.560, vs. 0.019 μg/mg; IQR 0.004-0.118, p < 0.001). Patients with tubulopathies, renal dysplasia/congenital anomalies of the kidney and urogenital tract, glomerulonephritis, and nephrotic syndrome (NS) in relapse had the greatest elevations (p ≤ 0.01). Patients with NS in remission, nephrolithiasis, polycystic kidney disease, transplant, or hypertension were not different from controls. Although all NS in relapse had higher apoAI excretion than in remission (0.159 vs. 0.0355 μg/mg, p = 0.01), this was largely driven by patients with focal segmental glomerulosclerosis (FSGS). Many patients, especially with FSGS, had increased urinary apoAI isoforms. Biopsies from FSGSpatients showed increased apoAI staining at proximal tubule brush border, compared to diffuse cytoplasmic distribution in minimal change disease. CONCLUSIONS:Children with kidney disease have variably increased urinary apoAI depending on underlying disease. Urine apoAI is particularly elevated in diseases affecting proximal tubules. Kidney disease is also associated with high molecular weight (HMW) apoAI isoforms in urine, especially FSGS. Whether abnormal urinary apoAI is a marker or contributor to renal disease awaits further study.
Authors: Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-09 Impact factor: 8.311
Authors: Roberto S Moreira; Maria Irigoyen; Talita R Sanches; Rildo A Volpini; Niels O S Camara; Denise M Malheiros; Maria H M Shimizu; Antonio C Seguro; Lucia Andrade Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-06-11 Impact factor: 3.619
Authors: Amit V Khera; Olga V Demler; Steven J Adelman; Heidi L Collins; Robert J Glynn; Paul M Ridker; Daniel J Rader; Samia Mora Journal: Circulation Date: 2017-04-27 Impact factor: 29.690
Authors: Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh Journal: JAMA Date: 2009-11-11 Impact factor: 56.272
Authors: L Calabresi; S Simonelli; P Conca; G Busnach; M Cabibbe; L Gesualdo; M Gigante; S Penco; F Veglia; G Franceschini Journal: J Intern Med Date: 2014-08-01 Impact factor: 8.989
Authors: Ana Carolina P Souza; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Yuning G Huang; Kenneth J Wilkins; Xuzhen Hu; Jonathan M Street; Alejandro Alvarez-Prats; Adam E Mullick; Amy P Patterson; Alan T Remaley; Thomas L Eggerman; Peter S T Yuen; Robert A Star Journal: Kidney Int Date: 2016-04 Impact factor: 10.612
Authors: Linda S May-Zhang; Valery Yermalitsky; Jiansheng Huang; Tiffany Pleasent; Mark S Borja; Michael N Oda; W Gray Jerome; Patricia G Yancey; MacRae F Linton; Sean S Davies Journal: J Biol Chem Date: 2018-04-30 Impact factor: 5.157
Authors: Conxita Jacobs-Cachá; Ander Vergara; Clara García-Carro; Irene Agraz; Nestor Toapanta-Gaibor; Gema Ariceta; Francesc Moreso; Daniel Serón; Joan López-Hellín; Maria José Soler Journal: Clin Kidney J Date: 2020-08-11